|
Trade Name | KANEKA LIXELLE BETA 2-MICROGLOBULIN APHERESIS COLUMN |
Classification Name | beta 2-microglobulin apheresis column |
Generic Name | beta 2-microglobulin apheresis column |
Applicant |
KANEKA PHARMA AMERICA LLC |
546 fifth ave., 21st floor |
new york, NY 10036 |
|
HDE Number | H130001 |
Date Received | 02/01/2013 |
Decision Date | 03/05/2015 |
Product Code | |
Docket Number | 15M-0909 |
Notice Date | 03/19/2015 |
Advisory Committee |
Gastroenterology |
Supplement Type | hde original |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for the lixelle® ß2-microglobulin apheresis column (also called the beta2-microglobulin apheresis column or ß2m). This device is indicated for the treatment of patients with clinically diagnosed dialysis-related amyloidosis (dra). |
Approval Order | Approval Order |
Summary | Summary of Safety And Probable Benefit |
Labeling | Labeling Labeling Part 2 |
Post-Approval Study | Show Report Schedule and Study Progress |
Supplements: |
S001 S002 S003 |